UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer

Nature communications, 2019-03, Vol.10 (1), p.1336-1336, Article 1336

2019

Volltextzugriff (PDF)

Recent Progress on Therapeutic Vaccines for Breast Cancer

Frontiers in oncology, 2022-06, Vol.12, p.905832-905832

2022

Volltextzugriff (PDF)

Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial

Frontiers in immunology, 2024-02, Vol.15, p.1210859-1210859

2024

Volltextzugriff (PDF)

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Scientific reports, 2017-04, Vol.7 (1), p.579-579, Article 579

2017

Volltextzugriff (PDF)

Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report

Frontiers in immunology, 2023-12, Vol.14, p.1277810

2023

Volltextzugriff (PDF)

Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e001925

2021

Volltextzugriff (PDF)

Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine

Frontiers in oncology, 2022-02, Vol.12, p.800484

2022

Volltextzugriff (PDF)

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer

Frontiers in oncology, 2022-11, Vol.12, p.1015232-1015232

2022

Volltextzugriff (PDF)

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer

Advanced science, 2023-01, Vol.10 (1), p.e2203298-n/a

2023

Volltextzugriff (PDF)

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study

Frontiers in oncology, 2021-10, Vol.11, p.693386-693386

2021

Volltextzugriff (PDF)

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma

Journal for immunotherapy of cancer, 2024-06, Vol.12 (6), p.e008611

2024

Volltextzugriff (PDF)

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Signal transduction and targeted therapy, 2024-06, Vol.9 (1), p.143-10

2024

Volltextzugriff (PDF)

Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9550-9550

2022

Volltextzugriff (PDF)

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Scientific reports, 2016-01, Vol.6 (1), p.20070-20070, Article 20070

2016

Volltextzugriff (PDF)

Lipid-insertion to enable targeting functionalization of paclitaxel loaded erythrocyte membrane nanoparticle by tumor-penetrating bispecific recombinant protein

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14047-e14047

2017

Volltextzugriff (PDF)

Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy

Journal of controlled release, 2015-02, Vol.200, p.188-200

2015

Volltextzugriff (PDF)

Abstract A20: A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of antigen-specific CTL in gastric cancer in vivo

Cancer immunology research, 2017-03, Vol.5 (3_Supplement), p.A20-A20

2017

Volltextzugriff (PDF)

Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment

International journal of nanomedicine, 2018-01, Vol.13, p.4961-4975

2018

Volltextzugriff (PDF)

AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.384-384

2021

Volltextzugriff (PDF)

Integration of simultaneous and cascade release of two drugs into smart single nanovehicles based on DNA-gated mesoporous silica nanoparticles

Chemical science (Cambridge), 2014-09, Vol.5 (11), p.4424-4433

2014

Volltextzugriff (PDF)

Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy

Oncology reports, 2017-04, Vol.37 (4), p.2063-2070

2017

Volltextzugriff (PDF)

A tumor-penetrating recombinant protein anti-EGFR-iRGD to enchance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e13526-e13526

2015

Volltextzugriff (PDF)

Genomic biomarker discovery of first-line gemcitabine/nabpaclitaxel treatment in Chinese advanced pancreatic carcinoma patients

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.436-436

2021

Volltextzugriff (PDF)

Camouflaging iRGD-EGFR anchored human cytotoxic T-lymphocyte membranes to the surface of nanoparticles combined with low-dose irradiation: New approach to enhance drug-delivery targeting in gastric cancer

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14076-e14076

2017

Volltextzugriff (PDF)

Combination drug release of smart cyclodextrin-gated mesoporous silica nanovehicles

Chemical communications (Cambridge, England), 2015-04, Vol.51 (33), p.7203-7206

2015

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(51)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(55)
Berichte
(2)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer

Recent Progress on Therapeutic Vaccines for Breast Cancer

Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial

sTRAIL-iRGD is a promising therapeutic agent for gastric cancer treatment

Making "cold" tumors "hot"- radiotherapy remodels the tumor immune microenvironment of pancreatic cancer to benefit from immunotherapy: a case report

Bifunctional iRGD-anti-CD3 enhances antitumor potency of T cells by facilitating tumor infiltration and T-cell activation

Case Report: Pathological Complete Response in a Lung Metastasis of Phyllodes Tumor Patient Following Treatment Containing Peptide Neoantigen Nano-Vaccine

Therapeutic effect and safety of individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer

Benefits of an Immunogenic Personalized Neoantigen Nanovaccine in Patients with High‐Risk Gastric/Gastroesophageal Junction Cancer

AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study

Single-arm study of camrelizumab plus apatinib for patients with advanced mucosal melanoma

First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial

Camrelizumab plus apatinib for patients with advanced mucosal melanoma: A prospective single-arm study

CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients

Lipid-insertion to enable targeting functionalization of paclitaxel loaded erythrocyte membrane nanoparticle by tumor-penetrating bispecific recombinant protein

Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy

Abstract A20: A tumor-penetrating recombinant protein anti-EGFR-iRGD enhance efficacy of antigen-specific CTL in gastric cancer in vivo

Anti-EGFR-iRGD recombinant protein modified biomimetic nanoparticles loaded with gambogic acid to enhance targeting and antitumor ability in colorectal cancer treatment

AGIG chemo-immunotherapy in patients with advanced pancreatic cancer: A single-arm, single-center, phase II study

Integration of simultaneous and cascade release of two drugs into smart single nanovehicles based on DNA-gated mesoporous silica nanoparticles

Tumor-penetrating peptide fused to a pro-apoptotic peptide facilitates effective gastric cancer therapy

A tumor-penetrating recombinant protein anti-EGFR-iRGD to enchance efficacy of paclitaxel in 3D multicellular spheroids and gastric cancer in vivo

Genomic biomarker discovery of first-line gemcitabine/nabpaclitaxel treatment in Chinese advanced pancreatic carcinoma patients

Camouflaging iRGD-EGFR anchored human cytotoxic T-lymphocyte membranes to the surface of nanoparticles combined with low-dose irradiation: New approach to enhance drug-delivery targeting in gastric cancer

Combination drug release of smart cyclodextrin-gated mesoporous silica nanovehicles

Suchergebnisse filtern